Literature DB >> 17542920

Clostridium difficile toxin expression is inhibited by the novel regulator TcdC.

Susana Matamouros1, Patrick England, Bruno Dupuy.   

Abstract

Clostridium difficile, an emerging nosocomial pathogen of increasing clinical significance, produces two large protein toxins that are responsible for the cellular damage associated with the disease. The precise mechanisms by which toxin synthesis is regulated in response to environmental change have yet to be discovered. The toxin genes (tcdA and tcdB) are located in a pathogenicity locus (PaLoc), along with tcdR and tcdC. TcdR is an alternative RNA polymerase sigma factor that directly activates toxin gene expression, while the inverse relationship between expression of tcdR, tcdA and tcdB genes on the one hand and tcdC on the other has led to the suggestion that TcdC somehow interferes with toxin gene expression. This idea is further supported by the finding that many recent C. difficile epidemic strains in which toxin production is increased carry a common tcdC deletion mutation. In this report we demonstrate that TcdC negatively regulates toxin synthesis both in vivo and in vitro. TcdC destabilizes the TcdR-containing holoenzyme before open complex formation, apparently by interaction with TcdR or TcdR-containing RNA polymerase holoenzyme or both. In addition, we show that the hypertoxigenicity phenotype of C. difficile epidemic strains is not due to their common 18 bp in-frame deletion in tcdC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17542920     DOI: 10.1111/j.1365-2958.2007.05739.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  97 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

2.  A multiplex, internally controlled real-time PCR assay for detection of toxigenic Clostridium difficile and identification of hypervirulent strain 027/ST-1.

Authors:  A M Hoegh; J B Nielsen; A Lester; A Friis-Møller; K Schønning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-22       Impact factor: 3.267

3.  Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes.

Authors:  Stéphanie Sirard; Louis Valiquette; Louis-Charles Fortier
Journal:  J Clin Microbiol       Date:  2011-09-28       Impact factor: 5.948

4.  Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.

Authors:  Thomas Akerlund; Ingela Persson; Magnus Unemo; Torbjörn Norén; Bo Svenungsson; Marlene Wullt; Lars G Burman
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

5.  Genotypic investigation of Clostridium difficile in Prince Edward Island.

Authors:  H Martin; L P Abbott; D E Low; B Willey; M Mulvey; J Scott Weese
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

Review 6.  Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen.

Authors:  Milena M Awad; Priscilla A Johanesen; Glen P Carter; Edward Rose; Dena Lyras
Journal:  Gut Microbes       Date:  2014

Review 7.  Clostridium difficile colitis: pathogenesis and host defence.

Authors:  Michael C Abt; Peter T McKenney; Eric G Pamer
Journal:  Nat Rev Microbiol       Date:  2016-08-30       Impact factor: 60.633

8.  The C-Terminal Domain of Clostridioides difficile TcdC Is Exposed on the Bacterial Cell Surface.

Authors:  Ana M Oliveira Paiva; Leen de Jong; Annemieke H Friggen; Wiep Klaas Smits; Jeroen Corver
Journal:  J Bacteriol       Date:  2020-10-22       Impact factor: 3.490

9.  Proline-dependent regulation of Clostridium difficile Stickland metabolism.

Authors:  Laurent Bouillaut; William T Self; Abraham L Sonenshein
Journal:  J Bacteriol       Date:  2012-12-07       Impact factor: 3.490

10.  Bacteriophage-mediated toxin gene regulation in Clostridium difficile.

Authors:  Revathi Govind; Govindsamy Vediyappan; Rial D Rolfe; Bruno Dupuy; Joe A Fralick
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.